MAXM and me. First, me. I'm not the kind of guy who presciently sells before bad news and posts about it. Instead, I like being different and cheerfully admit to my investment getting imolated by half. OK.
Now, could someone weigh in on my consternation about MAXM? I am (was) wholly prepared for debatable issues about statistical significance, efficacy, therapeutic doses of IL-2, subpopulations and so on, and further prepared to misunderstand those risks and nuances. In fact I was prepared to be labeled foolish and hopeful and naive about that stuff.
But....Grade 3-4 toxicities in 62% of patients with liver mets, the only possible label? I am surprised at this and feeling, what is a kind word...underinformed? So my question is where did I go wrong on toxicities. From the company's publications, did anyone expect this bit of bad news prospectively? Isn't a mere Grade 3, much less a Grade 4, toxiticity by definition a lousy quality of life?
I'd be happy to take this elsewhere, but you guys are, you know, smart. And I am trying mightily to get smarter without first running out of money. (Actually, I had a low basis.)
I have no ego. Go ahead...use the CAPS key.
--Wilder |
